- Previous Rank224
- Revenues ($M)$15,281.0
- Revenue Percent Change17.5%
- Profits ($M)$4,046.0
- Profits Percent Change37.6%
- Assets ($M)$35,480.0
- Employees8,852
The biopharmaceutical company is the maker of Thalomid and various other drugs that treat multiple myeloma, inflammatory diseases, and various forms of cancer.
Company Info
| CEO | Mark J. Alles |
| CEO Title | Chairman & Chief Executive Officer |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| HQ Location | Summit, N.J. |
| Website | http://www.celgene.com |
| Years on Fortune 500 List | 8 |
| Employees | 8,852 |
Celgene Rank History
placeholder
Key Financials (Last Fiscal Year)
| $ millions | % change | |
|---|---|---|
| Revenues ($M) | $15,281.0 | 17.5% |
| Profits ($M) | $4,046.0 | 37.6% |
| Assets ($M) | $35,480.0 | - |
| Total Stockholder Equity ($M) | $6,161.0 | - |
Profit Ratios
| Profit as % of Revenues | 26.5% |
| Profits as % of Assets | 11.4% |
| Profits as % of Stockholder Equity | 65.7% |
Earnings Per Share (Last Fiscal Year)
| Earnings Per Share ($) | 5.51 |
| EPS % Change (from 2017) | 51.4% |
| EPS % Change (5 year annual rate) | 26.7% |
| EPS % Change (10 year annual rate) | - |
Total Return
| Total Return to Investors (2018) | -38.6% |
| Total Return to Investors (5 year, annualized) | -5.4% |
| Total Return to Investors (10 year, annualized) | 8.8% |